Aurobindo Pharma delivered solid Q3 FY26 results, with consolidated revenue up 8.4% YoY to ₹8,646 Cr and net profit rising 7.6–8% to ₹910 Cr, led by strong Europe growth and stable US formulations despite some transient product softness.

Aurobindo Pharma Q3 FY26 – Key Numbers

• Consolidated:

  • Revenue: ₹8,646 Cr (+8.4% YoY).
  • EBITDA: ₹1,773 Cr (+9% YoY), margin 20.5% (+11 bps YoY).
  • Net profit: ₹910 Cr (+7.6–8% YoY).
  • EPS: ₹15.67 (+7.7% YoY).
• Standalone:
  • Revenue: ₹2,747 Cr (-5.4% YoY).
  • Net profit: ₹582 Cr (+23.3% YoY), EPS ₹10.02.
• Cash position: Net cash $251 Mn.

Segment Performance Breakdown

Pipeline: 7 new USFDA ANDA approvals (incl. 2 final from tentative); launched 9 US products; R&D spend ₹409 Cr (4.7% of sales); biosimilars targeting $50 Bn markets by 2032 (denosumab, omalizumab filings 2026).

Strengths

• Geographic diversification pays off: Europe +27.4% YoY offsets modest US (+2.2%) and API dip; ARV +22.4%.
• Margin stability: EBITDA margin holds at 20.5% (+11 bps YoY) amid pricing pressures.
• Pipeline momentum: 7 USFDA approvals, 9 US launches; strong biosimilar pipeline for high-value targets.
• R&D commitment: ₹409 Cr spend (4.7% sales) supports complex generics/biosimilars entry.
• Balance sheet strength: Net cash $251 Mn enables capex, acquisitions, dividends.

Risks

• US growth slowdown: Modest +2.2% amid competition, pricing erosion in generics.
• API revenue decline: -4.3% YoY signals headwinds in active ingredients segment.
• Standalone revenue dip: -5.4% YoY raises questions on core operations efficiency.
• Regulatory hurdles: USFDA scrutiny, biosimilar approval delays possible.
• Forex/macro sensitivity: 43% US revenue exposed to USD/INR volatility.